Starnet

Quick links to important sections

Starnet

Method of action: Drugs Used In Diabets

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Starnet

Quick Facts

Property Description
Active ingredient Nateglinide
Form Oral tablet
Pharmacological class Oral Hypoglycemic Agent (Meglitinide Class)
General purpose Meal time glucose regulator for Type 2 diabetes
Origin Synthetic D-phenylalanine derivative
Rx Status Prescription-only (Rx)

Defining Starnet: Classification and Origin

Starnet is a single-ingredient, prescription oral medication used in the management of Type 2 diabetes mellitus. Its active ingredient is Nateglinide, which is classified as an Oral Hypoglycemic Agent and an insulin secretagogue. Nateglinide belongs specifically to the Meglitinide class of drugs, which are structurally distinct from the sulfonylureas. The compound is a synthetic derivative of the amino acid D-phenylalanine, a structural characteristic clinically recognized for governing the drug's short-lived, transient activity.

What Form is Nateglinide Supplied In?

The active ingredient Nateglinide is supplied for administration exclusively as an oral tablet. This single-entity product ensures that the pharmacological action is derived entirely from the Nateglinide compound. This formulation contrasts with combination products, providing a highly focused therapeutic approach. The use of the oral tablet facilitates straightforward incorporation into a patient’s mealtime schedule, a distinctive factor when managing blood glucose.

Starnet's Role as a Targeted Meal Time Regulator

Starnet is characterized as a specialized meal time glucose regulator due to its rapid onset and notably short duration of action on pancreatic beta-cells. This unique pharmacokinetic profile is a key differentiating factor from longer-acting oral agents; it enables the drug to quickly promote insulin release, specifically in response to the intake of food. The general therapeutic purpose of this fast on-fast off effect is to provide effective control of the sugar spike known as postprandial hyperglycemia, reducing the potential for sustained high insulin levels after a meal.

What side effects are possible with Starnet?

Possible Side Effects and Safety Information

The safety profile of Starnet (Nateglinide) is characterized by the potential for hypoglycemia (low blood sugar), which is the primary and expected consequence of its glucose-lowering action. Regulatory documentation classifies non-severe episodes of hypoglycemia as common in patients taking the medication.

Officially Documented Common Adverse Reactions

In addition to hypoglycemia, the drug's regulatory safety labeling lists several other adverse reactions as common (occurring in ge 3% of patients in clinical trials). These events are grouped by the affected System-Organ Class (SOC) and include:

  • Infections and Infestations: Upper respiratory tract infection, flu symptoms.
  • Musculoskeletal and Connective Tissue Disorders: Back pain, joint pain (arthropathy).
  • Nervous System Disorders: Dizziness.
  • Gastrointestinal Disorders: Diarrhea.

Serious Adverse Reactions and Postmarketing Events

Severe hypoglycemia is explicitly documented as a serious adverse reaction, potentially leading to seizures or death. Furthermore, postmarketing surveillance, for which frequency is generally not known, has included reports of serious events such as Hepatobiliary Disorders (e.g., cholestatic hepatitis, jaundice) and severe Hypersensitivity Reactions (e.g., urticaria).

Safety Considerations for Specific Populations

Official labeling mandates specific cautions for certain patient populations. Use requires caution in individuals with hepatic impairment (chronic liver disease) due to the increased risk of hypoglycemia. Patients with severe renal impairment are also noted to be at an increased risk of low blood sugar. The medication is contraindicated in patients with Type 1 Diabetes Mellitus and Diabetic Ketoacidosis.

Overdose and Emergency Response

An overdose of Starnet (Nateglinide) is documented by regulatory authorities as resulting in an exaggerated glucose-lowering effect that manifests as severe hypoglycemia. The core official profile centers on the symptoms associated with this metabolic crisis.

Officially Documented Manifestations and Severe Outcomes

The clinical presentation listed in regulatory labeling involves initial symptoms such as sweating, trembling, dizziness, fatigue, nausea, and palpitations (rapid heartbeat). Official documents state that if unaddressed, this severe metabolic reduction can progress to life-threatening neurological outcomes, including profound confusion, stupor, seizures, and eventually coma. The regulatory profile notes that certain patient populations, such as elderly patients and those with severe renal impairment, may demonstrate an increased susceptibility to this severe glucose reduction.

Emergency Actions Required

Regulatory guidance mandates that emergency medical attention must be sought immediately when overdose is suspected. It is specified that emergency services must be called immediately if the affected individual experiences loss of consciousness or a seizure, as these represent severe, life-threatening manifestations. In a clinical setting, no specific chemical antidote is known for Nateglinide. Official treatment is described as symptomatic and supportive management, which focuses on the intravenous administration of glucose to rapidly reverse the exaggerated effect. Continuous hospital monitoring and observation are required due to the risk of recurrent hypoglycemia.

Therapeutic Uses of Starnet

What Starnet Treats: Main Uses and Benefits

Starnet is generally considered relevant across therapeutic domains where additional symptomatic support is needed. It may be part of symptomatic management in conditions characterized by periods of heightened symptoms and episodic or fluctuating manifestations. The primary goal is to provide supportive relief that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

This form of short-term symptomatic assistance is commonly applied in clinical scenarios involving acute or disruptive symptom patterns, and it is used to help with symptom clusters that may become intense or disruptive, such as those related to physical discomfort, systemic imbalance, and heightened physiological activity. Managing episodic conditions often involves distinct acute and preventative strategies. Starnet's role is to support patients during difficult episodes by easing distress and may assist with maintaining functional stability during temporary functional strain.


Quick Fact: Relief for Episodic Discomfort

Regulatory References

  1. Greater Manchester Medicines Management Group (GMMMG) Headache Guideline

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Starnet (Nateglinide) — Official Regulatory Information

Nateglinide is officially indicated as an adjunct to diet and exercise to improve glycemic control only in adults with Type 2 diabetes mellitus. Use is strictly defined by regulatory contraindications and population-specific restrictions.


Populations for whom use is contraindicated

Contraindication Status
Type 1 Diabetes Mellitus Contraindicated
Diabetic Ketoacidosis Contraindicated
Severe Hepatic Impairment Contraindicated
Pregnancy and Lactation Contraindicated / Not Recommended
Known Hypersensitivity Contraindicated

Age-Related and Condition-Specific Eligibility

  • Pediatric Population (Under 18): Use is not recommended; safety and efficacy have not been established.
  • Geriatric Patients: No dose adjustments are necessary based on age alone, though greater sensitivity is recognized.
  • Moderate Hepatic Impairment: Use with caution is recommended. No dose adjustment is required for mild impairment.
  • Renal Impairment: No dose adjustment is required for mild to moderate impairment, but caution is necessary in severe cases.

Connection to the overall eligibility profile

The regulatory profile strictly limits Nateglinide use to adults with Type 2 diabetes. Absolute exclusion is mandated for Type 1 diabetes, diabetic ketoacidosis, pregnancy, lactation, and severe liver dysfunction. Furthermore, use is formally restricted or advised against in specific patient groups, such as the pediatric population where efficacy has not been proven, and patients with moderate hepatic or severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Starnet’s official interaction profile is characterized by effects on its metabolism and by pharmacodynamic effects on blood glucose levels. The drug is predominantly cleared by the hepatic enzymes CYP2C9 and, to a lesser extent, CYP3A4.

Co-administration with inhibitors of CYP2C9 (e.g., Fluconazole, Amiodarone) may increase Nateglinide exposure (AUC), which can enhance its blood-glucose-lowering effect. Conversely, CYP inducers (e.g., Rifampin, Phenytoin) may reduce Nateglinide exposure, potentially diminishing its effect.

Pharmacodynamic and Substance Interactions

A number of medicinal products are documented to alter the drug's activity:

  • Enhancing the Hypoglycemic Effect: Agents such as NSAIDs, Salicylates, MAO Inhibitors, and non-selective beta-blockers are listed as increasing the risk of hypoglycemia.
  • Reducing the Hypoglycemic Effect: Agents such as Thiazide diuretics, Corticosteroids, and Thyroid Products may reduce its glucose-lowering action.
  • Masking Hypoglycemia: Beta-adrenergic-blocking agents and similar drugs may blunt the signs and symptoms of hypoglycemia.

Interactions with non-medicinal substances are also officially noted. Alcohol may increase the blood-glucose-lowering effect. Certain herbal products (e.g., St John’s Wort) and supplements (e.g., Gymnema Sylvestre) are documented to modify the drug's effect.

Contraindications and Population Notes

The regulatory label states that Starnet is contraindicated in patients with Type 1 diabetes mellitus and diabetic ketoacidosis. Use in severe hepatic impairment is also a contraindication. Furthermore, individuals identified as CYP2C9 poor metabolizers may experience higher systemic concentrations and an associated increased risk of adverse reactions.

Mechanism of Action

Regulating Receptor-Mediated Signaling

Starnet initiates its effect by acting within domains involving receptor- or enzyme-mediated signaling, selectively engaging mechanisms that regulate specific, defined biological processes. This action establishes altered regulation within targeted cellular pathways, modifying early molecular steps that shape systemic physiological effects.

Modulating Key Pathways

The compound modulates central pathways regulating specific physiological responses by altering specific transmitter or mediator activity. By engaging mechanisms that influence feedback regulation, Starnet can initiate or suppress signaling sequences, which modifies the threshold of mediator activity.

Adjusting Systemic Function

Ultimately, Starnet's action results in measurable physiological adjustments, primarily by inducing a measured reduction in baseline physiological activity. This effect emerges from the targeted pathway adjustment and engagement of mechanisms that regulate defined processes at a foundational molecular level.

Dosage and Administration Information

How to Use Starnet

Starnet (Nateglinide) is administered following a strict regimen designed to synchronize its action with food intake. The usage protocol centers on the medication’s fast-acting nature as a mealtime regulator.


Administration Scope

Feature Guideline
Route of administration Oral administration of the tablet.
Dosing schedule The starting dose is typically 60 mg, taken three times daily (TID). The usual maintenance dose is 120 mg, also taken TID.
Timing in relation to meals Doses must be taken 1 to 30 minutes before a main meal (i.e., before breakfast, lunch, and dinner).
Preparation requirements The tablet is swallowed whole with water.
Missed-dose rule If a meal is missed, the dose scheduled for that specific meal must be skipped to avoid misalignment of the medicine's activity with food intake.

Usage Patterns and Special Populations

Frequency Pattern: Starnet is consistently used three times daily, a frequency pattern that supports its role in regulating postprandial glucose levels. It is used as part of a long-term management plan for chronic conditions.

Population Adjustments: Use is not recommended for patients under 18 years of age due to limited available data. For individuals with hepatic impairment, an initial dose of 60 mg is recommended for those with mild-to-moderate conditions, while use is generally avoided in severe impairment.

Procedural Structure: The instructions establish a controlled, meal-dependent administration protocol that mandates three daily doses timed precisely before food intake. The consistency in timing and dose management is central to the standardized use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Starnet

The clinical evaluation of Starnet (nateglinide) was studied for its role as an oral agent in the research context of Type 2 Diabetes Mellitus. The research evidence describes which types of studies have been conducted, what outcomes were monitored, and what remains uncertain regarding its long-term impact on health.


Evidence for use in Type 2 Diabetes Mellitus

The research base for Starnet is primarily derived from short- to intermediate-term Randomized Controlled Trials (RCTs). These studies explored how Starnet, either alone or alongside other diabetes treatments, compared to a placebo (a sugar pill) or to other study treatments. The research examined how the medication was observed in adult populations with Type 2 Diabetes to affect key indicators of blood sugar control.

Evaluation of Mealtime Glucose Control (Postprandial Glucose)

Studies focusing on mealtime control were designed to monitor the spike in blood sugar that occurs shortly after eating, known as Postprandial Glucose (PPG). Research examined its impact during this period. Data show patterns related to a change in these PPG levels during the observed short-term study intervals. This research has contributed to understanding symptom patterns related to temporary physiological imbalance in response to food intake.

Evaluation of Long-Term Average Glucose (HbA1c)

Beyond mealtime control, research examined the effect of Starnet on the Glycosylated Hemoglobin (HbA1c) marker, which provides an estimate of average blood sugar control over the previous two to three months. Studies monitored changes in HbA1c measurements over typical follow-up durations of 8 to 24 weeks. The data show patterns related to a change in this marker, and these findings help contribute to the broader evidence landscape regarding overall glucose measurements in the observed populations.


Long-Term Research and Clinical Outcomes Follow-up

While short-term studies examined blood sugar levels, other research explored the use of Starnet over extended periods to investigate its potential impact on major clinical events. Large-scale outcomes trials, which followed participants for up to five years, were studied for assessing whether Starnet was associated with a change in the risk of macrovascular events.

One of these extended studies, conducted in individuals with risk factors for developing diabetes and cardiovascular issues, monitored participants over several years. The data from this research reported that the group receiving Starnet was not associated with a statistically different outcome in the composite measurement of cardiovascular events or in the overall incidence of developing diabetes, compared to the group that did not receive it. Crucially, controlled clinical studies have not established conclusive evidence regarding any change in macrovascular risk.


Research Gaps and Remaining Uncertainties

A key research limitation noted in regulatory reviews is the lack of conclusive evidence that Starnet affects macrovascular outcomes, such as reducing the risk of heart attack or stroke. Official labeling notes that clinical studies have not established conclusive evidence of macrovascular risk reduction. This is a key area where data are still emerging, meaning that research provides context but not individual predictions regarding long-term cardiovascular protection.

Frequently Asked Questions (FAQ)

Common questions about Starnet (FAQ)

Q: How long does the effect of a Starnet dose usually last?

Starnet is characterized by its fast-acting nature and short duration. According to official product information, its blood sugar regulating activity typically lasts about four hours following administration. This rapid action is what makes the medication suitable for mealtime regulation.

Q: Are there any foods or vitamins that should be avoided with Starnet?

Official regulatory guidance focuses on the timing of Starnet rather than specific foods to avoid. The guidance notes that the drug should be taken 1 to 30 minutes right before a main meal. If a meal is skipped, the corresponding dose is generally advised to be skipped to maintain proper alignment. Official documents do not typically list general vitamins that must be avoided.

Q: Do older adults (seniors) need a different approach to taking Starnet?

According to official labeling, no dose adjustment is necessary for older adults based on age alone. However, regulatory documents recognize that older patients may show increased sensitivity to the medication. This population is noted to have a greater potential risk of experiencing hypoglycemia (low blood sugar).

Q: What are the most commonly reported side effects of Starnet?

The most commonly reported adverse events (those occurring in 3% or more of patients in studies), as documented in official regulatory documents, include hypoglycemia (low blood sugar) as the primary risk. Other common events noted are upper respiratory tract infection, back pain, flu symptoms, joint pain, dizziness, and diarrhea.

Q: How should Starnet be stopped, according to official information?

Official patient information strongly emphasizes that the decision to stop or change Starnet therapy must be made only under the supervision of a healthcare provider. This careful approach is necessary to ensure the safe and proper ongoing management of the underlying condition.

Q: Is Starnet a controlled substance?

Starnet's active ingredient, Nateglinide, is classified as a prescription-only medication. It is not listed as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration (DEA).

Q: Does Starnet interact with common over-the-counter pain relievers?

Regulatory documents indicate that Starnet can interact with certain common over-the-counter pain relievers. Specifically, drug categories like NSAIDs and Salicylates are noted as agents that may enhance the blood-glucose-lowering effect, potentially increasing the risk of hypoglycemia.

Q: Is Starnet the same type of medicine as [similar competing drug name]?

Starnet belongs to the Meglitinide class of oral hypoglycemic agents. Official regulatory documents describe this class as structurally distinct from other common types of blood sugar regulators, such as sulfonylureas.

Q: Is Starnet used for any conditions other than the main ones listed?

The official regulatory indication for Starnet is strictly limited to use as an adjunct to diet and exercise for the purpose of improving glycemic control in adults with Type 2 diabetes mellitus. Regulatory documents do not define its use for other conditions.

Q: Can Starnet cause weight gain or weight loss?

According to official documents detailing the results of clinical studies, weight gain has been reported as an adverse event associated with Starnet. However, its reported frequency is generally lower than the most common side effects of the medication.

Q: What's the difference between Starnet and generics (if available)?

Both Starnet (brand name) and its generic versions contain the identical active ingredient, Nateglinide. Regulatory agencies require generic versions to be bioequivalent to the brand-name product. This means they are expected to work in the same way and deliver the same clinical benefit.

Q: Is Starnet known to affect sleep patterns or cause insomnia?

Official regulatory documents have reported sleep disturbances, including insomnia, as adverse events in patients taking Starnet. These are generally reported with a lower incidence than the most common side effects.

Q: Are there any specific safety warnings for people with kidney problems using Starnet?

Official labeling advises caution for patients who have severe renal impairment (kidney problems), as this patient group may have an increased risk of hypoglycemia (low blood sugar). For mild-to-moderate impairment, a dose adjustment is typically not required according to the official product information.

Q: Is Starnet safe for people with high blood pressure?

High blood pressure itself is not listed as a contraindication in official regulatory documents. However, the label notes that certain medications used to treat high blood pressure, such as beta-adrenergic blocking agents, may potentially mask the usual signs and symptoms of hypoglycemia.

Q: Is it normal to feel tired when first starting Starnet?

Official documentation lists adverse events, including general symptoms such as fatigue and dizziness, which were reported by some patients in clinical studies. These are known events that may occur when beginning the medication.

Q: Why is Starnet sometimes described as 'selective'?

Starnet is described as selective because its active ingredient, Nateglinide, acts to quickly and reversibly regulate specific molecular targets. It engages certain potassium channels on pancreatic beta cells, which initiates insulin release specifically around mealtime.

Q: What does the research say about Starnet's effectiveness compared to no treatment?

Research evidence, primarily from short- to intermediate-term studies, describes that Starnet was observed to affect key indicators of blood sugar control compared to placebo (no treatment). These studies examined the medication's impact on Postprandial Glucose (PPG), which is the sugar spike after a meal, and Glycosylated Hemoglobin (HbA1c), which reflects average control.

Q: Does Starnet require special monitoring or blood tests?

Regulatory guidance states that patients taking Starnet should undergo regular monitoring. This typically includes checking immediate blood glucose levels and performing HbA1c measurements to assess overall blood sugar control over time.

Q: Can Starnet affect a person's ability to drive or operate machinery?

Official labeling advises caution regarding driving or operating heavy machinery. This caution is based on the risk of hypoglycemia (low blood sugar) and related events such as dizziness, which may temporarily affect mental alertness and coordination.

Q: Is Starnet approved for use during pregnancy or breastfeeding?

Official regulatory information states that the use of Starnet is contraindicated or not recommended during both pregnancy and lactation (breastfeeding). The safety and efficacy of the medication for the mother or the developing fetus/infant have not been established in these populations.

Q: Are headaches a common side effect of Starnet?

Headache has been reported as an adverse event in official regulatory documentation based on clinical studies. However, its reported incidence is generally lower than the most common side effects listed, such as hypoglycemia and upper respiratory tract infection.

Q: Can Starnet be crushed or split?

Official administration instructions state that Starnet tablets should be swallowed whole with water. The medication’s intended action depends on this method of administration.

Q: Is it safe to take Starnet if I have diabetes?

Starnet is specifically indicated and studied only for the management of Type 2 diabetes mellitus. It is strictly contraindicated (prohibited) for use in patients who have Type 1 diabetes mellitus or diabetic ketoacidosis.

Q: What is the expected duration of treatment with Starnet?

Official usage patterns describe Starnet as being part of a long-term management plan for chronic conditions. The exact duration of treatment will be determined by a healthcare provider based on the individual's overall treatment strategy.

Q: Does Starnet have a boxed warning (black box warning)?

The official FDA Prescribing Information for Starnet does not contain a Boxed Warning. This specific regulatory warning is used to call attention to very serious risks associated with a drug.

Q: What is the difference between a side effect and an adverse reaction for Starnet?

In official regulatory documents, the terms 'side effect' and 'adverse reaction' are often used broadly to describe an undesirable event that occurs while taking the medication. The official labeling lists the specific data collected from studies under the heading Adverse Reactions.

Q: Is Starnet more effective for some patient types than others?

Official regulatory information is based on clinical studies primarily focused on adult populations with Type 2 diabetes mellitus. The official labeling does not specify that the medication is expected to have different effects based on patient type within the indicated population.

Q: Can Starnet affect appetite?

Changes in appetite, including both decreased and increased appetite, have been reported as adverse events in official regulatory documentation. These events were observed in clinical studies but are not listed among the most commonly reported side effects.

How should Starnet be stored and disposed of?

How to Store and Dispose of Starnet

The storage and disposal of Starnet (Nateglinide) tablets must comply strictly with regulatory requirements to maintain product stability and ensure safety.


Storage Requirements

Starnet must be stored at Controlled Room Temperature, which is typically between 20 C and 25 C (68 F and 77 F). The product must be protected from moisture and light and should not be stored above 30 C. The tablets should be kept in their original container and stored securely out of the sight and reach of children.


Disposal Instructions

Expired or unused Starnet tablets should be disposed of via a drug take-back program or a DEA-registered collector. The medication is not recommended for flushing. If a take-back program is unavailable, tablets can be mixed with an undesirable substance, sealed in a container, and discarded in the household trash, following general pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Starnet found in:

A-Z Index: